Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Zevra Therapeutics
ZVRA
Zevra Therapeutics
Sluggish Diagnosis Will Constrain Expansion But Bring Cautious Optimism
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
25 Aug 25
Updated
25 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$18.00
47.7% undervalued
intrinsic discount
25 Aug
US$9.41
1Y
30.5%
7D
4.5%
Loading
1Y
30.5%
7D
4.5%
Author's Valuation
US$18.0
47.7% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$18.0
47.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-90m
254m
2014
2017
2020
2023
2025
2026
2028
Revenue US$254.5m
Earnings US$116.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
34.92%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$116.57m
Earnings '28
x
12.22x
PE Ratio '28
=
US$1.42b
Market Cap '28
US$1.42b
Market Cap '28
/
65.30m
No. shares '28
=
US$21.81
Share Price '28
US$21.81
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$17.92
Fair Value '25
